US · SNN
Smith & Nephew plc
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Watford WD18 8YE
- Website
- smith-nephew.com
Price · as of 2024-12-31
$31.16
Market cap 16.13B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $37.37 | +19.93% |
| Intrinsic Value(DCF) | $11.65 | -62.61% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $11.96 | -61.62% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $16.72 | $38.12 | $1.94 | $6.23 | $17.89 |
| 2011 | $14.55 | $37.95 | $0.98 | $6.31 | $20.37 |
| 2012 | $16.40 | $38.50 | $1.07 | $7.92 | $8.24 |
| 2013 | $24.07 | $39.43 | $0.76 | $4.41 | $16.17 |
| 2014 | $26.31 | $38.95 | $0.30 | $1.72 | $15.78 |
| 2015 | $26.07 | $38.32 | $0.00 | $0.00 | $7.98 |
| 2016 | $24.99 | $39.15 | $0.27 | $3.38 | $15.67 |
| 2017 | $31.12 | $42.02 | $0.68 | $4.74 | $17.61 |
| 2018 | $32.55 | $41.21 | $0.28 | $2.37 | $16.67 |
| 2019 | $38.09 | $43.56 | $0.00 | $1.33 | $17.45 |
| 2020 | $34.58 | $37.20 | $0.00 | $0.00 | $0.00 |
| 2021 | $27.66 | $37.61 | $0.05 | $0.60 | $25.95 |
| 2022 | $26.44 | $33.22 | $0.00 | $0.00 | $4.14 |
| 2023 | $26.23 | $36.68 | $0.00 | $0.00 | $17.21 |
| 2024 | $29.13 | $37.37 | $0.00 | $0.00 | $11.96 |
AI valuation
Our deep-learning model estimates Smith & Nephew plc's (SNN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $37.37
- Current price
- $31.16
- AI upside
- +19.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$11.65
-62.61% upside
Graham-Dodd
—
— upside
Graham Formula
$11.96
-61.62% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNN | Smith & Nephew plc | $31.16 | 16.13B | +20% | -63% | — | -62% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| CNC | Centene Corporation | $44.88 | 22.07B | -25% | +2,787% | — | — | -3.28 | 1.10 | 0.11 | -4.43 | — | 4.77 | 12.24% | -3.91% | -3.43% | -28.80% | -30.25% | -8.34% | 0.94 | -11.24 | 1.68 | 1.68 | -0.17 | -31585.00% | 1944.00% | -98184.00% | 19.73% | 0.24 | 17.29% | 0.00% | 0.00% | 22.61% | -2.99 | 5.27 | 0.12 | 2.79 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| FMS | Fresenius Medical Care AG… | $23.46 | 13.52B | -1% | -60% | +12% | -19% | 11.94 | 0.82 | 0.60 | 7.06 | 14.46 | -21.51 | 25.62% | 9.31% | 4.98% | 6.78% | 6.03% | 3.03% | 0.76 | — | 1.26 | 0.76 | 3.11 | 8261.00% | 151.00% | 54.00% | 14.52% | 0.41 | 7.11% | 3.47% | 41.50% | 13.67% | 11.43 | 12.31 | 1.06 | 1.31 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| MEDP | Medpace Holdings, Inc. | $451.76 | 12.82B | -29% | +273% | -84% | -6% | 29.25 | 28.75 | 5.22 | 22.70 | 139.42 | -55.74 | 30.06% | 21.14% | 17.83% | 70.23% | 171.74% | 22.13% | 0.55 | — | 0.74 | 0.67 | -0.43 | 2098.00% | 1997.00% | 1915.00% | 5.17% | 0.53 | 263.19% | 0.00% | 0.00% | 6.95% | 24.21 | 18.99 | 5.12 | 6.85 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| RPRX | Royalty Pharma plc | $46.21 | 19.8B | +84% | -35% | -81% | -50% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| TEM | Tempus AI, Inc. | $53.25 | 9.2B | +3% | +24,028% | — | — | -37.91 | 18.91 | 7.30 | -42.05 | — | -27.80 | 69.64% | -18.76% | -19.27% | -89.48% | -62.74% | -15.31% | 1.66 | -3.40 | 3.13 | 2.86 | -0.95 | -6937.00% | 8341.00% | 1325.00% | -2.57% | -0.59 | -76.13% | 0.00% | 0.00% | 0.03% | -39.18 | -39.10 | 7.35 | 3.76 |
| THC | Tenet Healthcare Corporat… | $239.39 | 21.04B | -32% | -53% | -100% | -28% | 15.18 | 5.06 | 1.00 | 7.36 | — | -2.57 | 41.41% | 16.46% | 6.60% | 33.54% | 19.78% | 4.80% | 3.12 | — | 1.76 | 1.22 | 2.39 | -5263.00% | 312.00% | 12670.00% | 11.85% | 0.79 | 16.87% | 0.00% | 0.00% | 11.50% | 9.02 | 12.51 | 1.48 | 2.07 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- CEO
- Deepak S. Nath
- Employees
- 17.35K
- Beta
- 0.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($11.65 ÷ $31.16) − 1 = -62.61% (DCF, example).